Friedreich Ataxia Repeat Expansion, FXN (frataxin) Gene Analysis
Friedreich’s ataxia (FRDA) is an autosomal recessive disorder that affects children and young adults with symptoms appearing before 25 years of age. Disease is caused by homozygous guanine-adenine-adenine trinucleotide (GAA) repeat expansion that causes deficiency of frataxin, a small nuclear genome-encoded mitochondrial protein. There is a clear correlation between size of the expanded repeat and severity of the phenotype. Frataxin is a mitochondrial protein that plays a role in iron homeostasis. Deficiency of frataxin results in mitochondrial iron accumulation, defects in specific mitochondrial enzymes, enhanced sensitivity to oxidative stress, and eventually free-radical mediated mitochondrial damage, axonal degeneration cell death. Therefore, FRDA is considered a new nuclear encoded mitochondrial disease.
Friedreich’s ataxia is a slowly progressive neurodegenerative disorder affecting 1in 50,000 individuals mainly in the Caucasian population. The incidence is much lower in Asians and African ancestries. Most common syndromes associated with disease are ataxia, loss of deeptendon reflexes, muscle weakness (atrophy) often associated with scoliosis, foot deformities, cardiomyopathy and diabetes mellitus in less cases. Screening patients for mutation X25 resulted in identification of a trinucleotide repeat expansion (GAA) within the first intron of Frataxing gene located in the chromosome 9q13. Normal alleles contain between 5-33 repeats, whereas expanded alleles contain 120-1700 repeats which is characteristic of this disease. The repeats >34 results in permutation. The disease or mutation is transmitted maternally. Both genes/alleles must be affected (homozygous) to develop disease. Heterozygous where only one gene is affected will result in carrier phenotype, but will not develop disease. Molecular testing for expansion of GAA triple nucleotide repeat behind 60 repeats would confirm the diagnosis.
- Diagnosis of Friedreich’s ataxia
- Screening for carriers
- Prenatal screening
- Homozygous (when both and the same alleles of the frataxin genes are affected) mutation or compound heterozygous (when two alleles, but not identical of the frataxin gene are affected) >60 repeats confirms disease
- Heterozygous mutation (only one frataxin gene/allele is affected) does not cause disease, but confirms carrier
- Triple repeats from 34-60 gives permutation genotype
| Category | GAA Triple Repeats |
| Normal Allele | 5–33 |
| Permutation | 34–60 |
| Disease allele | 66 to >1700 |
Whole blood collected in lavender top tube (EDTA), buccal swab and other tissues.
Stability
- Ambient: 3-7 days
- Refrigerated: 7-14 days
- J Neuropathol Exp Neurol. 2013 Feb;72(2):78-90. [PMID: 23334592]
- World J Cardiol. 2019 Jan 26;11(1):1-12. [PMID: 30705738]
- Biochem J. 2013 Aug 1;453(3):321-36. [PMID: 23849057]
- J Neurol Sci. 2011 Apr 15;303(1-2):1-12. [PMID: 21315377]
- Pediatr Neurol. 2003 May;28(5):335-41. [PMID: 12878293]
- Int J Mol Med. 2001 Jun;7(6):581-9. [PMID: 11351269]
- Hum Genet. 2000 Jan;106(1):86-92. [PMID: 10982187]